Trends and Outcomes of Metabolic Surgery in Adolescents with BMI ≥ 50 vs < 50 kg/m2: A Retrospective Study Using the MBSAQIP Database - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Analysis of Metabolic Surgery Outcomes in Adolescents with Severe Obesity: A Retrospective Review of the MBSAQIP Database

  • By

  • Pattharasai Kachornvitaya

  • Mélissa V Wills

  • Juan S Barajas-Gamboa

  • Salvador Navarrete

  • Ricard Corcelles

  • Andrew Strong

  • Suthep Udomsawaengsup

  • Matthew Kroh

  • Jerry Dang

  • Valentin Mocanu

  • July 19, 2025

Share

  • 1

    Adolescent obesity is a significant public health issue, with 20.6% of U.S. teenagers classified as obese.

  • 2

    Metabolic and bariatric surgery (MBS) is an effective intervention for adolescents with severe obesity when non-surgical methods fail.

  • 3

    The use of MBS in adolescents remains low, particularly for those with BMI ≥ 50 kg/m2, despite their high risk for health complications.

  • 4

    This study evaluates the short-term safety and outcomes of MBS in adolescents with BMI ≥ 50 kg/m2 compared to those with lower BMI.

  • 5

    Findings aim to inform clinical decisions and expand access to MBS for adolescents facing severe obesity-related health risks.

Original Source(s)

Trends and Outcomes of Metabolic Surgery in Adolescents with BMI ≥ 50 vs < 50 kg/m2: A Retrospective Study Using the MBSAQIP Database

  • by Pattharasai Kachornvitaya, Mélissa V Wills, Juan S Barajas-Gamboa, Salvador Navarrete, Ricard Corcelles, Andrew Strong, Suthep Udomsawaengsup, Matthew Kroh, Jerry Dang, Valentin Mocanu

  • July 19, 2025

Related Content

Correction to: Anatomical and surgical factors associated with postoperative hydrocephalus after central neurocytoma resection: a large single-center cohort study

Perioperative Depression and Anxiety Care in Older Patients: A Randomized Clinical Trial

FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.